824 related articles for article (PubMed ID: 29051064)
1. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma.
Li TF; Li K; Zhang Q; Wang C; Yue Y; Chen Z; Yuan SJ; Liu X; Wen Y; Han M; Komatsu N; Xu YH; Zhao L; Chen X
Biomaterials; 2018 Oct; 181():35-52. PubMed ID: 30071380
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-polyglycerol-nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy.
Li TF; Xu YH; Li K; Wang C; Liu X; Yue Y; Chen Z; Yuan SJ; Wen Y; Zhang Q; Han M; Komatsu N; Zhao L; Chen X
Acta Biomater; 2019 Mar; 86():381-394. PubMed ID: 30654213
[TBL] [Abstract][Full Text] [Related]
4. Monocyte-mediated chemotherapy drug delivery in glioblastoma.
Wang C; Li K; Li T; Chen Z; Wen Y; Liu X; Jia X; Zhang Y; Xu Y; Han M; Komatsu N; Zhao L; Chen X
Nanomedicine (Lond); 2018 Jan; 13(2):157-178. PubMed ID: 29173008
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin conjugated with nanodiamonds and in free form commit glioblastoma cells to heterodromous fates.
Chen Z; Wang C; Li TF; Li K; Yue Y; Liu X; Xu HZ; Wen Y; Zhang Q; Han M; Komatsu N; Xu YH; Zhao L; Chen X
Nanomedicine (Lond); 2019 Feb; 14(3):335-351. PubMed ID: 30676239
[TBL] [Abstract][Full Text] [Related]
6. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X
J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
8. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme.
Yang FY; Wong TT; Teng MC; Liu RS; Lu M; Liang HF; Wei MC
J Control Release; 2012 Jun; 160(3):652-8. PubMed ID: 22405901
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
[TBL] [Abstract][Full Text] [Related]
10. Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection.
Graham-Gurysh E; Moore KM; Satterlee AB; Sheets KT; Lin FC; Bachelder EM; Miller CR; Hingtgen SD; Ainslie KM
Mol Pharm; 2018 Mar; 15(3):1309-1318. PubMed ID: 29342360
[TBL] [Abstract][Full Text] [Related]
11. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
[TBL] [Abstract][Full Text] [Related]
12. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
13. Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells.
Mukherjee S; Fried A; Hussaini R; White R; Baidoo J; Yalamanchi S; Banerjee P
J Exp Clin Cancer Res; 2018 Jul; 37(1):168. PubMed ID: 30041669
[TBL] [Abstract][Full Text] [Related]
14. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
[TBL] [Abstract][Full Text] [Related]
15. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Elastin-Like Polypeptides for Tumor Targeted Delivery of Doxorubicin to Glioblastoma.
Dragojevic S; Mackey R; Raucher D
Molecules; 2019 Sep; 24(18):. PubMed ID: 31489879
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-polyglycerol-nanodiamond conjugates disrupt STAT3/IL-6-mediated reciprocal activation loop between glioblastoma cells and astrocytes.
Chen Z; Yuan SJ; Li K; Zhang Q; Li TF; An HC; Xu HZ; Yue Y; Han M; Xu YH; Komatsu N; Zhao L; Chen X
J Control Release; 2020 Apr; 320():469-483. PubMed ID: 31987922
[TBL] [Abstract][Full Text] [Related]
18. Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models.
Kovacs Z; Werner B; Rassi A; Sass JO; Martin-Fiori E; Bernasconi M
J Control Release; 2014 Aug; 187():74-82. PubMed ID: 24878186
[TBL] [Abstract][Full Text] [Related]
19. LRP1-mediated pH-sensitive polymersomes facilitate combination therapy of glioblastoma in vitro and in vivo.
He C; Zhang Z; Ding Y; Xue K; Wang X; Yang R; An Y; Liu D; Hu C; Tang Q
J Nanobiotechnology; 2021 Jan; 19(1):29. PubMed ID: 33482822
[TBL] [Abstract][Full Text] [Related]
20. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.
Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A
Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
